Literature DB >> 12689773

Presymptomatic compensation in Parkinson's disease is not dopamine-mediated.

Erwan Bezard1, Christian E Gross, Jonathan M Brotchie.   

Abstract

The symptoms of Parkinson's disease (PD) appear only after substantial degeneration of the dopaminergic neuron system (e.g. an 80% depletion of striatal dopamine)--that is, there is a substantive presymptomatic period of the disease. It is widely believed that dopamine-related compensatory mechanisms are responsible for delaying the appearance of symptoms. Recent advances in understanding the presymptomatic phase of PD have increased our understanding of these dopamine-related compensatory mechanisms and have highlighted the role of non-dopamine-mediated mechanisms both within and outside the basal ganglia. This increased knowledge of plasticity within cortical-basal-ganglia-thalamocortical circuitry as dopaminergic neuron degeneration progresses has implications for understanding plasticity in neural circuits generally and, more specifically, for developing novel therapeutics or presymptomatic diagnostics for PD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12689773     DOI: 10.1016/S0166-2236(03)00038-9

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  109 in total

1.  Nociceptin/Orphanin FQ Inhibits the Survival and Axon Growth of Midbrain Dopaminergic Neurons Through a p38-MAPK Dependent Mechanism.

Authors:  Louise M Collins; Giorgia Dal Bo; Mariangela Calcagno; Jimena Monzón-Sandoval; Aideen M Sullivan; Humberto Gutierrez; Michele Morari; Gerard W O'Keeffe
Journal:  Mol Neurobiol       Date:  2015-12-21       Impact factor: 5.590

2.  Complexity of electrocortical activity as potential biomarker in untreated Parkinson's disease.

Authors:  Giovanni Mostile; Loretta Giuliano; Valeria Dibilio; Antonina Luca; Calogero Edoardo Cicero; Vito Sofia; Alessandra Nicoletti; Mario Zappia
Journal:  J Neural Transm (Vienna)       Date:  2018-12-03       Impact factor: 3.575

3.  A new mouse model to study compensatory mechanisms that support normal motor function in Parkinson's disease.

Authors:  Xiang Bai; Stacy A Hussong
Journal:  J Biochem Pharmacol Res       Date:  2014-06

4.  Effects of L-Dopa and pramipexole on plasticity induced by QPS in human motor cortex.

Authors:  Hiroyuki Enomoto; Yasuo Terao; Suguru Kadowaki; Koichiro Nakamura; Arata Moriya; Setsu Nakatani-Enomoto; Shunsuke Kobayashi; Akioh Yoshihara; Ritsuko Hanajima; Yoshikazu Ugawa
Journal:  J Neural Transm (Vienna)       Date:  2015-02-07       Impact factor: 3.575

5.  Altered expression and subcellular distribution of GRK subtypes in the dopamine-depleted rat basal ganglia is not normalized by l-DOPA treatment.

Authors:  M Rafiuddin Ahmed; Evgeny Bychkov; Vsevolod V Gurevich; Jeffrey L Benovic; Eugenia V Gurevich
Journal:  J Neurochem       Date:  2007-11-07       Impact factor: 5.372

Review 6.  A scale-free systems theory of motivation and addiction.

Authors:  R Andrew Chambers; Warren K Bickel; Marc N Potenza
Journal:  Neurosci Biobehav Rev       Date:  2007-05-03       Impact factor: 8.989

7.  Changes in network activity with the progression of Parkinson's disease.

Authors:  Chaorui Huang; Chengke Tang; Andrew Feigin; Martin Lesser; Yilong Ma; Michael Pourfar; Vijay Dhawan; David Eidelberg
Journal:  Brain       Date:  2007-04-30       Impact factor: 13.501

8.  Are there adaptive changes in the human brain of patients with Parkinson's disease treated with long-term deep brain stimulation of the subthalamic nucleus? A 4-year follow-up study with regional cerebral blood flow SPECT.

Authors:  Stelvio Sestini; Alberto Pupi; Franco Ammannati; Ramat Silvia; Sandro Sorbi; Antonio Castagnoli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-05-04       Impact factor: 9.236

Review 9.  The role of neuroplasticity in dopaminergic therapy for Parkinson disease.

Authors:  Xiaoxi Zhuang; Pietro Mazzoni; Un Jung Kang
Journal:  Nat Rev Neurol       Date:  2013-04-16       Impact factor: 42.937

10.  Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease.

Authors:  Chris C Tang; Kathleen L Poston; Vijay Dhawan; David Eidelberg
Journal:  J Neurosci       Date:  2010-01-20       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.